ArticleImmunoTargets and therapy2025
Multi-Dimensional Characterization of Programmed Cell Death Patterns for Prognostic Stratification and Therapeutic Insights in Sepsis.
Article in ImmunoTargets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The multidimensional signaling of ELANE: from congenital hematopoietic failure to immune microenvironment crosstalk and targeted interventions.Cell communication and signaling : CCS · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a complex and heterogeneous syndrome characterized by dysregulated immune responses and multiple forms of programmed cell death (PCD). Comprehensive understanding of the PCD landscape may provide insights into prognosis and therapeutic targets, whereas its role in sepsis is not well-explored. Methods: Using the microarray dataset for sepsis (GSE65682), we systematically profiled 14 PCD patterns in sepsis and stratified patients into molecular subtypes with distinct immune landscapes and clinical outcomes. PCD-related prognostic signature was developed and validated across multiple cohorts. Single-cell and multi-organ transcriptomic analyses were conducted to elucidate cellular heterogeneity and temporal dynamics. Molecular docking was used to explore interactions between active compounds of Simiao Yongan Decoction (SMYAD) and key PCD-related proteins. Results: Two clusters with differential transcriptional programs and immune infiltration patterns were identified, in which Cluster 1 showed poorer prognosis. We then developed a seven-gene signature ( Conclusion: This study delineates the multi-dimensional role of PCD in sepsis, establishes a reliable prognostic model with strong predictive value, and highlights SMYAD as a potential multi-target therapy. These findings provide new avenues for risk stratification and suggest the promise of integrating PCD biology with adjunctive immunomodulatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.